A detailed history of Arthur M. Cohen & Associates, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Arthur M. Cohen & Associates, LLC holds 4,010 shares of BMY stock, worth $229,893. This represents 0.04% of its overall portfolio holdings.

Number of Shares
4,010
Holding current value
$229,893
% of portfolio
0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

BUY
$39.66 - $51.75 $159,036 - $207,517
4,010 New
4,010 $207,000
Q1 2024

Apr 22, 2024

BUY
$47.98 - $54.4 $191,440 - $217,056
3,990 New
3,990 $216,000
Q4 2019

Jan 10, 2020

SELL
$49.21 - $64.19 $196,347 - $256,118
-3,990 Closed
0 $0
Q3 2019

Nov 04, 2019

BUY
$42.77 - $50.71 $170,652 - $202,332
3,990 New
3,990 $202,000
Q2 2019

Jul 29, 2019

SELL
$44.62 - $49.34 $390,201 - $431,478
-8,745 Closed
0 $0
Q1 2019

May 07, 2019

SELL
$45.12 - $53.8 $1.77 Million - $2.11 Million
-39,191 Reduced 81.76%
8,745 $417,000
Q3 2018

Oct 22, 2018

SELL
$55.19 - $62.25 $194,875 - $219,804
-3,531 Reduced 6.86%
47,936 $2.98 Million
Q2 2018

Aug 13, 2018

BUY
$50.53 - $62.98 $7,074 - $8,817
140 Added 0.27%
51,467 $2.85 Million
Q1 2018

Apr 23, 2018

BUY
$59.92 - $68.98 $1.27 Million - $1.47 Million
21,273 Added 70.78%
51,327 $3.15 Million
Q4 2017

Mar 06, 2019

SELL
$59.94 - $65.35 $1.47 Million - $1.6 Million
-24,443 Reduced 44.85%
30,054 $1.56 Million
Q4 2017

Jan 26, 2018

SELL
$59.94 - $65.35 $113,886 - $124,164
-1,900 Reduced 3.37%
54,497 $3.34 Million
Q3 2014

Nov 08, 2017

BUY
N/A
56,397
56,397 $3.6 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $122B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Arthur M. Cohen & Associates, LLC Portfolio

Follow Arthur M. Cohen & Associates, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arthur M. Cohen & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Arthur M. Cohen & Associates, LLC with notifications on news.